31 May I 18:30 – 19:45 CEST
AbbVie - Tailor-made Care – Why Benefit: risk Assessment Should Drive Individualized Treatment Decisions
Session details

31 May I 18:30 – 19:45 CEST
Medscape Education Global (Supported by UCB) - Raising the Bar: Optimizing Outcomes in Spondylarthritis
Session details

31 May I 18:30 – 19:45 CEST
Janssen: IL-23 in PsA: connecting the domains of skin, gut, and joint
Session details

31 May I 18:30 – 19:45 CEST
GSK - Is there a “window of opportunity" in SLE?
Session details

31 May I 18:30 – 19:45 CEST
AstraZeneca - Writing a new chapter in long-term lupus care
Session details

31 May I 18:30 – 19:45 CEST
Sobi - The many faces of inflammation: which cytokine should I target, when, and why?
Session details

 

1 June I 08:15 – 09:30 CEST

AbbVie - Tailoring PsA Therapy to Fit the Patient – Are Emerging Therapies Part of Your Collection?

Session details

 

1 June I 08:15 – 09:30 CEST

Lilly : Finding the right treatment for the right patient: what similarities and key differences among RA, PsA and axSpA determine treatment decisions

Session details

 

1 June I 08:15 – 09:30 CEST

Novartis - Getting to the root of PsA and axSpA

Session details

 

1 June I 08:15 – 09:30 CEST

GSK - Shielding against shingles: how do we optimize care for our patients?

Session details

 

1 June I 08:15 – 09:30 CEST

AstraZeneca - Anifrolumab in SLE – perspectives from the real world

Session details

 

1 June I 08:15 – 09:30 CEST

EUSA - Unexplained lymphadenopathies: how a multidisciplinary approach can lead to a better diagnosis

Session details

 

1 June I 17:30 – 18:45 CEST

AbbVie - SpA on the Runway - A Front Row Seat for a Closer Look at the Latest Trends

Session details

 

1 June I 17:30 – 18:45 CEST

Pfizer - Connections between the gut, joint and spine: evidence and experience with JAK inhibitors

Session details

 

1 June I 17:30 – 18:45 CEST

UCB - The time is NOW! Aiming for higher treatment targets in PsA and axSpA

Session details

 

1 June I 17:30 – 18:45 CEST

Janssen : Moving closer to optimal pain management and timing intervention in PsA

Session details

 

1 June I 17:30 – 18:45 CEST

Boehringer Ingelheim - Optimising the management of patients with autoimmune disease-related ILDs through interdisciplinary discussions

Session details

 

1 June I 17:30 – 18:45 CEST

Galapagos - JAK to reality: seeking clarity in RA

Session details

 

1 June I 17:30 – 18:45 CEST

Celltrion Healthcare - Infliximab IV to SC: Mainstay Therapy in Rheumatology

Session details

 

1 June I 17:30 – 18:45 CEST

Vifor - Targeting unmet needs in ANCA-associated vasculitis – can we do better?     

Session details

 

2 June I 08:15 – 09:30 CEST
Pfizer - Unpacking the data: who are the appropriate patients with RA for a JAK inhibitor?
Session details

2 June I 08:15 – 09:30 CEST

Lilly - The Great Debate: Force of Habit vs. Innovative Approach in the management of inflammatory rheumatic diseases

Session details

 

2 June I 08:15 – 09:30 CEST

Medac - Improving first-line therapy of RA patients with optimized methotrexate

Session details

 

2 June I 08:15 – 09:30 CEST

GSK - How Can We Tackle the Early Drivers of Organ Damage and Excess Mortality in SLE?

Session details

 

2 June I 08:15 – 09:30 CEST

Roche - Inspired to move mountains: optimising care in systemic lupus

Session details

 

2 June I 08:15 – 09:30 CEST

Otsuka - Lupus Nephritis: can we talk about a change of perspective today?

Session details

 

2 June I 08:15 – 09:30 CEST

Kyverna - CAR T Cell Therapy in B Cell Driven Autoimmune Diseases

Session details

 

2 June I 17:30 – 18:45 CEST

CSF: The ”Case” for JAK Inhibitors- How JAK inhibition can be optimised in the treatment of varying RA patient populations, using case studies.

Session details

 

2 June I 17:30 – 18:45 CEST

Fresenius Kabi - Creating a Masterpiece in RA Management: How will new biosimilars shift the focus to alternative treatment strategies for your patients?

Session details

31 May I 15:45 – 16:15 CEST
Boehringer Ingelheim – “Monitoring and management of lung fibrosis in patients with autoimmune diseases”
Session details

31 May I 15:45 – 16:15 CEST

GSK - Raising ambitions with clinical remission in EGPA

Session details

 

31 May I 15:45 – 16:15 CEST

Vifor - What the Rheumatologist needs to know about the kidney in ANCA-associated vasculitis

Session details

 

1 June I 09:45 – 10:15 CEST

Janssen: Partners in managing PsA: collaboration with Gastroenterology

Session details

 

1 June I 09:45 – 10:15 CEST

GSK - Is there a “window of opportunity” in SLE?

Session details

1 June I 15:00 – 15:30 CEST

UCB - Facing the Challenges of the Impact of Gender in SpA

Session details

 

1 June I 15:00 – 15:30 CEST

Novartis - Advancing AOSD care: expert opinion on the latest guidelines

Session details

 

1 June I 15:00 – 15:30 CEST

GSK - Can Disease Modification Help Us Tackle Organ Damage and Excess Mortality in SLE?

Session details

 

2 June I 09:45 – 10:15 CEST
Janssen - ​What would you do? An interactive discussion on PsA scenarios
Session details

2 June I 09:45 – 10:15 CEST
Galapagos - Burning questions: the practical use of JAK inhibitors in RA
Session details

2 June I 09:45 – 10:15 CEST

Vifor - Shared decision making in ANCA-associated vasculitis

Session details

2 June I 15:00 – 15:30 CEST

AstraZeneca - Treat to Target: how biologics can help?

Session details